Abcuro absorbs $42m in series A-1 round

Jan 12, 2021 • Jordan Williams

Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

US-based autoimmune disease and cancer drug developer Abcuro has completed a $42m series A-1 round co-led by investment vehicles for pharmaceutical firm Sanofi and healthcare provider Mass General Brigham.

Sanofi Ventures and Mass General Brigham Ventures were joined in the round by Pontifax Venture Capital, Hongsen Investment Group, RA Capital Management and Samsara BioCapital.

Abcuro is developing immunotherapies to treat autoimmune diseases and cancer. It will use the funding to advance its lead drug candidates to the clinical development stage…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

CVC DIRECTORY

Find details about global CVC units in the CVC Directory

SPECIAL REPORT

Bumpy road: Self-driving cars make a cautious comeback

Events

Webinar: Designing a winning CVC platform – Engagement, venture development, operations

Jan 15, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: CVC Investment Programs

Apr 8 -
Apr 10, 2025
Online

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.